BAJAJHCARE2025-01-012025-03-31BAJAJHCARE2025-03-31BAJAJHCARE2024-03-31BAJAJHCARE2024-04-012025-03-31BAJAJHCARE2025-01-012025-03-31in-capmkt:OtherExpenses1MemberBAJAJHCARE2024-04-012025-03-31in-capmkt:OtherExpenses1MemberBAJAJHCARE2025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1BAJAJHCARE2024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain1BAJAJHCARE2024-12-31RelatedPartyTransactionDomain1BAJAJHCARE2025-03-31RelatedPartyTransactionDomain1BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain2BAJAJHCARE2024-12-31RelatedPartyTransactionDomain2BAJAJHCARE2025-03-31RelatedPartyTransactionDomain2BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain3BAJAJHCARE2024-12-31RelatedPartyTransactionDomain3BAJAJHCARE2025-03-31RelatedPartyTransactionDomain3BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain4BAJAJHCARE2024-12-31RelatedPartyTransactionDomain4BAJAJHCARE2025-03-31RelatedPartyTransactionDomain4BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain5BAJAJHCARE2024-12-31RelatedPartyTransactionDomain5BAJAJHCARE2025-03-31RelatedPartyTransactionDomain5BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain6BAJAJHCARE2024-12-31RelatedPartyTransactionDomain6BAJAJHCARE2025-03-31RelatedPartyTransactionDomain6BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain7BAJAJHCARE2024-12-31RelatedPartyTransactionDomain7BAJAJHCARE2025-03-31RelatedPartyTransactionDomain7BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain8BAJAJHCARE2024-12-31RelatedPartyTransactionDomain8BAJAJHCARE2025-03-31RelatedPartyTransactionDomain8BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain9BAJAJHCARE2024-12-31RelatedPartyTransactionDomain9BAJAJHCARE2025-03-31RelatedPartyTransactionDomain9BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain10BAJAJHCARE2024-12-31RelatedPartyTransactionDomain10BAJAJHCARE2025-03-31RelatedPartyTransactionDomain10BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain11BAJAJHCARE2024-12-31RelatedPartyTransactionDomain11BAJAJHCARE2025-03-31RelatedPartyTransactionDomain11BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain12BAJAJHCARE2024-12-31RelatedPartyTransactionDomain12BAJAJHCARE2025-03-31RelatedPartyTransactionDomain12BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain13BAJAJHCARE2024-12-31RelatedPartyTransactionDomain13BAJAJHCARE2025-03-31RelatedPartyTransactionDomain13BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain14BAJAJHCARE2024-12-31RelatedPartyTransactionDomain14BAJAJHCARE2025-03-31RelatedPartyTransactionDomain14BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain15BAJAJHCARE2024-12-31RelatedPartyTransactionDomain15BAJAJHCARE2025-03-31RelatedPartyTransactionDomain15BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain16BAJAJHCARE2024-12-31RelatedPartyTransactionDomain16BAJAJHCARE2025-03-31RelatedPartyTransactionDomain16BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain17BAJAJHCARE2024-12-31RelatedPartyTransactionDomain17BAJAJHCARE2025-03-31RelatedPartyTransactionDomain17BAJAJHCARE2025-01-012025-03-31RelatedPartyTransactionDomain18BAJAJHCARE2024-12-31RelatedPartyTransactionDomain18BAJAJHCARE2025-03-31RelatedPartyTransactionDomain18BAJAJHCARE2025-01-012025-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares539872BAJAJHCARENOTLISTEDINE411U01027BAJAJ HEALTHCARE LIMITEDMain BoardEquity2024-04-012025-03-312025-05-262025-05-20INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2025-05-2616:10:002025-05-2616:52:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-02-11https://www.bajajhealth.com/policies/falsefalseDuring the period ended 31.03.2025, there is no default.2025-01-012025-03-31AuditedStandalone1544725000135716000168044100010049090000-652230001570600006075800075310000330407000156322100011722000001172200000129000012900000115930000-8803000-4651000-415200001117780003451700014629500015791600053.673.59-0.13-0.133.543.460.00480.00440.0365 <BR> 3. The above audited financial results for the Year Ended 31 March 2025 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards Ind AS,as prescribed under Section 133 of the Companies Act 2013 Act read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI Listing obligations and disclosure requirements Regulations,2015 as amended. <BR> <BR> 4. The Company deals in pharmaceuticals products formulations and active pharmaceutical ingredients components which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals. 1. The above Financial Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 26 May 2025. <BR> <BR> <BR> 2. The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. <BR> <BR> <BR> <BR> <BR> 5. In the previous financial year ended 31 March 2024, the Board of Directors had approved to sale or disposal of undertaking or units on going concern basis, situated at plot no. N92, L 9 3 , T30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D 2 CH 42 and D 2 CH 43 Dahej industrial area, GIDC, Bharuch, Gujarat which were acquired under SARFAESI ACT, 2022 from Saraswat Bank and plot no. E 62 and E 63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale or disposal under Ind AS 105 Non current Assets Held for Sale and Discontinued Operations. The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale, the assets have been recorded at their fair value on the date these assets has been classified as held for sale. Out of these, one unit situated at plot no. N92 was sold during the Quarter ended 31 March 2024. The total value of assets classified as held for sale represents lower of carrying value or fair value. <BR> <BR> The financial information from discontinued operations: <BR> Particulars Quarter Ended Year Ended <BR> 31 March 2025 31 Dec 2024 31 March 2024 31 March 2025 31 March 2024 <BR> Total Income A 37.81 65.40 380.70 58.07 1,784.51 <BR> Total Expenses B 50.22 183.13 1,720.79 459.18 10,503.47 <BR> Loss before Tax from Discontinued Operations 88.03 117.73 1,340.09 401.11 8,718.96 <BR> Tax Expense Credit from Discontinued Operations D 46.51 206.71 1,547.70 57.78 1,772.31 <BR> Loss after Tax from Discontinued Operations 41.52 324.44 207.61 343.33 6,946.65 <BR> <BR> 6. The Board of Directors the Company in their meeting held on 10 July 2024 and the shareholders of the company in ExtraOrdinary General Meeting EGM held on Wednesday, 07 August, 2024 through Video Conferencing VC or Other Audio Visual Means OAVM approved, the issue of 40,44,852 Equity Shares at Rs 338 per share to Person s belonging to non promoter category on preferential basis and the issue of convertible equity warrants 20,79,409 at Rs. 338 to Person s belonging to promoter category as well as non promoter category on preferential basis. The object of the issue is to repayment of term loan, investment in capital expenditure and general corporate purpose. The Company has also obtained the in principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd. On 19 September 2024, post approval from Board, the Company has alloted 39,84,852 no. of equity shares and has also filed the relevant form with Registrar of Companies. The uncalled amount of share warrants as at 31 March 2025 is Rs. 5,271.30 lakhs. <BR> <BR> <BR> 7. The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities. <BR> Particulars Rs. in Lakhs <BR> Repayment and prepayment of secured or unsecured loans from bank and NBFC 15,000.00 <BR> General corporate purpose 225.90 <BR> Total 15,225.90 <BR> <BR> 8. During the previous year, the Company had written off inventories pertaining to certain covid portfolio products owing to continued lower demand, on a conservative basis. <BR> <BR> <BR> 9. Subsequent to the year ended 31 March 2025, the Company acquired Genrx Pharmaceuticals Private Limited which was under liquidation on a going concern basis. <BR> <BR> <BR> 10. The Board of Directors have recommended a Final dividend of 20% i.e. Rs. 1.00 Only per equity share on the face value of Rs. 5 each for the financial year ended 31 March 2025, subject to approval of shareholders in the ensuing Annual General Meeting. <BR> <BR> 11. Previous year or period figures have been regrouped to make them comparable with the current year or period figures, which are not material. <BR> 2024-04-012025-03-31AuditedStandalone5426024000194044000562006800030710900000-206637000570583000279044000279178000116673300051599910004600770000460077000030789000307890000429288000-40111000-5778000-343330000394955000137010004086560001579160005014.4514.26-1.16-1.1413.2913.120.00480.00440.0365Other Expenses330407000Other Expenses11667330002365594000344850000018887000000330000056085000561180001889520005729800027213340001618877000025167420002603800018470000033431800028955680003395850004854030000755098000833046200015791600045037260004661642000466164200064665100025400006491910004981000069900100015795910008440100087033000095473100010496600026392880007074100012633000272266200024715700036688200008330462000The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals.279044000-178495000-6832800000110204000000-509900000002791780000000129446000-38562000000000-40111000-503380000-19801300026206400000045859000021620500000000000110000011538500000000000000000000050590000-38925000-14815100000149697500000000450000000170280500012910002759800027904400000-637630004291000042910002174700026038000Items that will not be reclassified to profit or loss4612700046127000Items that will not be reclassified to profit or loss1830900018309000116100004608000003451700013701000Bajaj Healthcare Limited******Mr. Sajankumar Bajaj******Chairman & Managing DirectorRemunerationNA1974800000Bajaj Healthcare Limited******Mr. Anil Jain******Managing DirectorRemunerationNA1374800000Bajaj Healthcare Limited******Mr. Dhanajay Hatle******Whole-Time DirectorRemunerationNA182400000Bajaj Healthcare Limited******Ms. Namrata Bajaj******Whole-Time DirectorRemunerationNA86200000Bajaj Healthcare Limited******Mr. Pakshal Jain******Whole-Time DirectorRemunerationNA116400000Bajaj Healthcare Limited******Mr. Hemant Karnik******Non-Executive Independent DirectorAny other transactionSitting Fees for Board & Committee MeetingsNA9300000Bajaj Healthcare Limited******Mr. Ram Banarse******Non-Executive Independent DirectorAny other transactionSitting Fees for Board & Committee MeetingsNA8800000Bajaj Healthcare Limited******Mr. Sandeep Shah******Non-Executive Independent DirectorAny other transactionSitting Fees for Board & Committee MeetingsNA3500000Bajaj Healthcare Limited******Mr. Yaqoob Ali******Non-Executive Independent DirectorAny other transactionSitting Fees for Board & Committee MeetingsNA000Bajaj Healthcare Limited******Mrs. Kejal Shah******Non-Executive Independent DirectorAny other transactionSitting Fees for Board & Committee MeetingsNA1500000Bajaj Healthcare Limited******Mrs. Nihita Bajaj Kumar******Daughter of Mr. Sajankumar Bajaj, Chairman & Managing Director & Sister of Ms. Namrata Bajaj, Whole-Time DirectorAny other transactionLegal & Professional Fees1500000Approved by the Audit Committee60000000Bajaj Healthcare Limited******Ms. Khushi Jain******Daughter of Mr. Anil Jain, Managing Director & Sister of Mr. Pakshal Jain, Whole-Time DirectorAny other transactionLegal & Professional Fees1200000Approved by the Audit Committee30000000Bajaj Healthcare Limited******Mrs. Dhanshree D Hatle******Wife of Mr. Dhananjay Hatle, Whole-Time DirectorAny other transactionLegal & Professional Fees500000Approved by the Audit Committee23100000Bajaj Healthcare Limited******Mrs. Harshavi Pakshal Jain******Wife of Mr. Pakshal Jain, Whole-Time Director & Daughter-in-law of Mr. Anil Jain, Managing DirectorRemunerationNA86600000Bajaj Healthcare Limited******Mr. Sajankumar Bajaj******Chairman & Managing DirectorLoan500000000Approved by the Audit Committee12500000528000528000Loan05yearsUnsecuredCorporate Business PurposesBajaj Healthcare Limited******Ms. Apurva Bandivadekar******Company Secretary (Resigned as on 31.01.2025)RemunerationNA11700000Bajaj Healthcare Limited******Mr. Dayashankar Patel******Chief Financial Officer (Resigned as on 15.04.2025)RemunerationNA114500000Bajaj Healthcare Limited******Ms. Monica Tanwar******Company Secretary (Appointed as on 11.02.2025)RemunerationNA1190000053455000AuditedtrueWalker Chandiok Co & LLPtrue2025-05-31